Business

Investors could do ‘a lot worse’ than FedEx here, Jim Cramer says

Products You May Like

CNBC’s Jim Cramer on Monday told investors that while the market has yet to overcome the challenges threatening to create a recession, FedEx stock might be able to weather the turbulence.

“You might think FedEx would be a helpless victim of high gas prices, potential e-commerce plateau, a [Federal Reserve]-mandated slowdown. That would be wrong. This company’s taking control of its own destiny. … I think you could do a lot worse,” he said.

The “Mad Money” host said that while FedEx has struggled with supply chain disruptions and performing as well as it did during the height of the pandemic, the company is on the up and up.

FedEx reported mixed results in its latest quarter last week, beating slightly on earnings but missing on revenue, according to Refinitiv estimates. The company also issued a cheerful full-year guidance, projecting an increase in adjusted earnings. 

The transportation company also raised its dividend from 75 cents to $1.15.

“Companies don’t put through a 53% dividend boost when they’re worried about making their next quarter,” Cramer said. 

“Don’t forget, this is a market that only values profitable companies that reward their shareholders with dividends and buybacks,” he added.

Shares of FedEx fell 1.14% on Monday.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]

Products You May Like

Articles You May Like

The Federal Reserve cuts interest rates by another quarter point. Here’s what that means for you
Here’s what to know before ‘taking some risk off the table’ with bitcoin profits, advisor says
‘Returnuary’ — after the peak shopping season comes the busiest return month of the year
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.
CFPB takes aim at ‘bait-and-switch’ credit card rewards — consumers forfeit about $500 million worth each year

Leave a Reply

Your email address will not be published. Required fields are marked *